{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:09:10Z","timestamp":1722888550438},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Klin"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00063-010-1025-7","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T08:30:57Z","timestamp":1269678657000},"page":"155-162","source":"Crossref","is-referenced-by-count":1,"title":["Status der Behandlung der arteriellen Hypertonie unter Praxisbedingungen in deutschen Arztpraxen zum Zeitpunkt der Einf\u00fchrung des Renininhibitors Aliskiren","Current Status of Antihypertensive Drug Treatment in Primary Care Practice at Launch of the New Renin Inhibitor Aliskiren (RASANT)"],"prefix":"10.1007","volume":"105","author":[{"name":"Axel M\u00fcller, Johannes Schweizer, Wilhelm Kirch, Christoph Schindler f\u00fcr die RASANT-Studiengruppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Kirch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,28]]},"reference":[{"key":"1025_CR1","first-page":"1","volume":"10","author":"M.H. Alderman","year":"1997","unstructured":"Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. J Hypertens 1997;10:1\u20138.","journal-title":"J Hypertens"},{"key":"1025_CR2","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group.","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981\u201397.","journal-title":"JAMA"},{"key":"1025_CR3","doi-asserted-by":"crossref","unstructured":"Bergset J, Storozynsky E, Bisognano JD. Renin inhibition for hypertension: Selecting the right role for a new class of drug. Am J Ther:in press (Epub 2009 May 15).","DOI":"10.1097\/MJT.0b013e31819e9e9a"},{"key":"1025_CR4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1185\/03007990902804158","volume":"25","author":"M. Blumenstein","year":"2009","unstructured":"Blumenstein M, Romaszko J, Calderon A, et al. Antihypertensive efficacy and tolerability of aliskiren\/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin 2009;25:903\u201310.","journal-title":"Curr Med Res Opin"},{"key":"1025_CR5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"B.M. Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"1025_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1210\/er.2003-0001","volume":"24","author":"R.M. Carey","year":"2003","unstructured":"Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003;24:261\u201371.","journal-title":"Endocr Rev"},{"key":"1025_CR7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1056-8727(98)00020-8","volume":"13","author":"L. Davies","year":"1999","unstructured":"Davies L, Fulcher GR, Atkins A, et al. The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus. J Diabetes Complications 1999;13:45\u201351.","journal-title":"J Diabetes Complications"},{"key":"1025_CR8","unstructured":"Deutsche Hochdruckliga e.V. Leitlinien zur Behandlung der arteriellen Hypertonie. Heidelberg: Deutsche Hochdruckliga, 2008 ( http:\/\/www.hochdruckliga.de )."},{"key":"1025_CR9","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/01.HYP.35.6.1270","volume":"35","author":"S. Engeli","year":"2000","unstructured":"Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270\u20137.","journal-title":"Hypertension"},{"key":"1025_CR10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1357-2725(02)00311-4","volume":"35","author":"S. Engeli","year":"2003","unstructured":"Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35:807\u201325.","journal-title":"Int J Biochem Cell Biol"},{"key":"1025_CR11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF03344010","volume":"25","author":"E. Faloia","year":"2002","unstructured":"Faloia E, Gatti C, Camilloni MA, et al. Comparison of circulating and local adipose tissue reninangiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest 2002;25:309\u201314.","journal-title":"J Endocrinol Invest"},{"key":"1025_CR12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200767120-00008","volume":"67","author":"J.E. Frampton","year":"2007","unstructured":"Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007;67:1767\u201392.","journal-title":"Drugs"},{"key":"1025_CR13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","volume":"111","author":"A.H. Gradman","year":"2005","unstructured":"Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012\u20138.","journal-title":"Circulation"},{"key":"1025_CR14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","volume":"25","author":"R. Latini","year":"2004","unstructured":"Latini R, Masson S, Anand I, et al., for the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292\u20139.","journal-title":"Eur Heart J"},{"key":"1025_CR15","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","volume":"144","author":"J.L. Lavoie","year":"2003","unstructured":"Lavoie JL, Sigmund CD. Minireview: Overview of the renin-angiotensin system \u2014 an endocrine and paracrine system. Endocrinology 2003;144:2179\u201383.","journal-title":"Endocrinology"},{"key":"1025_CR16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"E.J. Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456\u201362.","journal-title":"N Engl J Med"},{"key":"1025_CR17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"E.J. Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"1025_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","volume":"1","author":"J.J.V. McMurray","year":"2008","unstructured":"McMurray JJV, Pitt B, Latini R et al. Effects of the oral direct reinin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17\u201324.","journal-title":"Circ Heart Fail"},{"key":"1025_CR19","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","volume":"356","author":"L.E. Neal","year":"2000","unstructured":"Neal LE, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pessure Lowering Treatment Trialists\u2019 Collaboration. Lancet 2000;356:1955\u201364.","journal-title":"Lancet"},{"issue":"Suppl2","key":"1025_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08038020802507290","volume":"17","author":"G. Nickenig","year":"2008","unstructured":"Nickenig G, Simanenkov V, et al. Efficacy of aliskiren\/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press 2008;17:Suppl 2:31\u201340.","journal-title":"Blood Press"},{"key":"1025_CR21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","volume":"49","author":"B.H. Oh","year":"2007","unstructured":"Oh BH, Mitchell J, Herron R, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"1025_CR22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S. Oparil","year":"2007","unstructured":"Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221\u20139.","journal-title":"Lancet"},{"key":"1025_CR23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-004-0731-6","volume":"60","author":"D. Pittrow","year":"2004","unstructured":"Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004;60:135\u201342.","journal-title":"Eur J Clin Pharmacol"},{"key":"1025_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","volume":"20","author":"J.L. Pool","year":"2007","unstructured":"Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypersensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11\u201320.","journal-title":"Am J Hypertens"},{"key":"1025_CR25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","volume":"119","author":"R.E. Schmieder","year":"2009","unstructured":"Schmieder RE, Phillip T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren \u2014 a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119:417\u201325.","journal-title":"Circulation"},{"key":"1025_CR26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","volume":"119","author":"S.D. Solomon","year":"2009","unstructured":"Solomon SD, Appelbaum E, Manning WJ, et al., for the Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530\u20137.","journal-title":"Circulation"},{"key":"1025_CR27","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F. Turnbull","year":"2003","unstructured":"Turnbull F, Neal B, Algert C, et al., the Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527\u201335.","journal-title":"Lancet"},{"key":"1025_CR28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","volume":"25","author":"F. Turnbull","year":"2007","unstructured":"Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007;25:951\u20138.","journal-title":"J Hypertens"},{"key":"1025_CR29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/VHRM.S3215","volume":"4","author":"P. Verdecchia","year":"2008","unstructured":"Verdecchia P, Angeli F, Mazzotta G, et al. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Healt Risk Manag 2008;4:971\u201381.","journal-title":"Vasc Healt Risk Manag"}],"container-title":["Medizinische Klinik"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-010-1025-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-010-1025-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-010-1025-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T08:39:36Z","timestamp":1685522376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-010-1025-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1007\/s00063-010-1025-7","relation":{},"ISSN":["0723-5003","1615-6722"],"issn-type":[{"type":"print","value":"0723-5003"},{"type":"electronic","value":"1615-6722"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}